Skip to Main Content

Paper Details

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis.
Crit Care Explor
0
2023
Acute Coronary Syndrome, Human, Kexin, Mice, PCSK9, Proprotein Convertase, Sepsis, Subtilisin, alirocumab, bacteremia sepsis, bacterial sepsis, cardiovascular disease, genetic LOF variants, human, loss-of-function (LOF) variants, mice, murine, participants, patients, proprotein convertase subtilisin/kexin type 9, sepsis
Author NameAffiliation
David J CareyGeisinger Medical Center
David J CareyGeisinger Medical Center
Lili MilaniInstitute of Genomics, University of Tartu
Kristian HveemK.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology
Kristian HveemHUNT Research Center, Norwegian University of Science and Technology
Anne Tybjaerg-HansenCopenhagen University Hospital - Rigshospitalet
Børge G NordestgaardCopenhagen University Hospital - Herlev Gentofte, University of Copenhagen
Keith R WalleyUniversity of British Columbia
Luca A Lotta
Aris BarasRegeneron Pharmaceuticals, Inc.
Aris Baras
  • 1 - 11

Datasets

Release 1.2